Publications by authors named "Meredith Regan"

Claim this Profile
N
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio, Meredith M Regan

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.
Pietro De Placido, Elizabeth Troll, Samuel M Niman, Sean Ryan, Ginny Mason, Meredith M Regan

Breast Cancer Res Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani, Meredith M Regan

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.
Ruth M O'Regan, Yue Ren, Yi Zhang, Natalia Siuliukina, Catherine A Schnabel, Meredith M Regan

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
Solange Peters, Meredith M Regan, Luis G Paz-Ares, Martin Reck, Hossein Borghaei

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
Karin Ribi, Bernard F Cole, Gini F Fleming, Barbara A Walley, Prudence A Francis, Meredith M Regan

Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, Jennell Palaia, Andriy Moshyk

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
Kristina Fanucci, Eren D Yeh, Ruichao Shi, Lei Qin, Camden P Bay, Meredith Regan

Breast Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.
Filipa Lynce, Samuel M Niman, Megumi Kai, Sean Ryan, Elizabeth Troll, Meredith M Regan

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00.
Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, Daniel J McGrail, Xuemei Xie, Meredith M Regan

iScience· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, Daniel Y C Heng, Wanling Xie, Meredith M Regan

JCO Oncol Pract· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials.
Elaine Chang, Haley Gittleman, Chi Song, Erik Bloomquist, Laura Fernandes, Meredith M Regan

JNCI Cancer Spectr· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.
Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli, Meredith M Regan

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
Giacomo Biganzoli, Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Meredith M Regan

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
Nicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, Prudence A Francis, Sally Baron-Hay, Meredith M Regan

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Mehul Gupta, Connor Wells, Meredith M Regan, Wanling Xie, Vishal Navani

Eur Urol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.
Stephen J Luen, Lauren C Brown, Courtney T van Geelen, Peter Savas, Roswitha Kammler, Meredith M Regan

JCO Precis Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to B. Tombal et al.
David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
Ruth M O'Regan, Yi Zhang, Gini F Fleming, Prudence A Francis, Roswitha Kammler, Meredith M Regan

JAMA Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.
Sagar A Patel, Dattatraya Patil, Joseph Smith, Christopher S Saigal, Mark S Litwin, Meredith M Regan

JAMA Netw Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Meredith M Regan

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Meredith M Regan

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Meredith M Regan

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
Eva Blondeaux, Wanling Xie, Luca Carmisciano, Silvia Mura, Valeria Sanna, Meredith M Regan

EClinicalMedicine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis